"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
- Patient Information:
Details with Side Effects
Patients should be counseled that antibacterial drugs including Sumycin '250' and Sumycin '500' Tablets (Tetracycline Hydrochloride Tablets) should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Sumycin '250' and Sumycin '500' Tablets (Tetracycline Hydrochloride Tablets) is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Sumycin '250' and Sumycin '500' Tablets (Tetracycline Hydrochloride Tablets) or other antibacterial drugs in the future.
Last reviewed on RxList: 2/8/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Sumycin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.